Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
Sebastian Stintzing
Consultant or Advisory Role - Merck KGaA; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Serono; Roche/Genentech
Andreas Jung
Honoraria - Merck KGaA
Lisa Rossius
No relevant relationships to disclose
Dominik Paul Modest
Consultant or Advisory Role - Amgen
Honoraria - Merck Serono; Roche
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Thomas Decker
No relevant relationships to disclose
Alexander Kiani
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Tobias Heintges
No relevant relationships to disclose
Markus Moehler
No relevant relationships to disclose
Werner Scheithauer
No relevant relationships to disclose
Thomas Kirchner
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi
Honoraria - Amgen; Merck Serono; Roche; Sanofi